Can a daily pill keep ankylosing spondylitis in check?
NCT ID NCT05861128
First seen Sep 24, 2026 · Last updated Sep 25, 2026 · Updated 1 time
Summary
Researchers are studying whether long-term treatment with jaktinib is safe and effective for people with active ankylosing spondylitis, a chronic inflammatory arthritis that causes back pain and stiffness. The trial enrolls adults who already completed an earlier 16-week jaktinib study and whose doctors judged they benefited from it. Participants take 100 mg of jaktinib by mouth twice daily for 32 weeks while researchers track side effects and measure improvements in pain, function, and disease activity.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- jaktinib, an oral drug that blocks Janus kinases (JAKs)
- What this could lead to
- If it works, this could give people with ankylosing spondylitis another long-term oral option to control pain and stiffness.
- What could go wrong
- This is an extension study that only enrolls people who already benefited from jaktinib, so it cannot show how the drug compares with other treatments. JAK-blocking drugs carry known risks of infection and blood clots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
207 people
The number who actually took part.
- Started
-
Nov 2023
- Finished
-
Mar 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * The investigators concluded that the participants continued to benefit from treatment with Jaktinib. * The participants have been fully informed and voluntarily signed informed consent. * The participants completed the ZGJAK029 study for 16 weeks of treatment and visitation and had good compliance. * The interval between the participants' first dose and the last dose of ZGJAK029 ≤ 4 weeks. Exclusion Criteria: * There were any grade ≥3 adverse events within 4 weeks prior to enrollment and no return to grade 1 or normal. * Within 4 weeks prior to enrollment, participants had the following infectious diseases: tuberculosis infection requiring treatment; HIV-positive, syphilis, HBV infection, HCV infection. * The investigators considered participants unsuitable for this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ankylosing spondylitis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Renji Hospital
Shanghai, Shanghai Municipality, 200001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can health literacy shield rheumatic disease patients from online health anxiety?
- Gut bacteria vs. spinal arthritis: can a probiotic calm inflammation?
- Can taekwondo kicks ease ankylosing spondylitis?
- Do rheumatic diseases quietly damage the Eye's oil glands?
- Could a gut microbiome transplant ease axial spondyloarthritis?
- Could a simple protein test unlock the secrets of joint disease?